礼来如何靠减肥药成为巨头

Thin Dave Ricks steered the 150-year-old drug giant to a $1 trillion market cap. Can he defeat pharma’s boom-and-bust cycle? By Madison Muller and Brad Stone Photographs by Kevin Serna W hen Dave Ricks became chief executive officer of Eli Lilly & Co. in 2017, he was facing an industry under siege. Americans held drug companies in lower esteem than air- lines, law firms and even the federal gov- ernment. President Donald Trump, then starting his first term, was excoriating them for their high prices. A mounting number of reports showed that soaring costs were even forcing some diabetics to ration insulin. Ricks, the 11th CEO in Lilly’s 150- year history, concedes that one was a public- relations nightmare. …